Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

448 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study.
Chiappella A, Martelli M, Angelucci E, Brusamolino E, Evangelista A, Carella AM, Stelitano C, Rossi G, Balzarotti M, Merli F, Gaidano G, Pavone V, Rigacci L, Zaja F, D'Arco A, Cascavilla N, Russo E, Castellino A, Gotti M, Congiu AG, Cabras MG, Tucci A, Agostinelli C, Ciccone G, Pileri SA, Vitolo U. Chiappella A, et al. Among authors: pavone v. Lancet Oncol. 2017 Aug;18(8):1076-1088. doi: 10.1016/S1470-2045(17)30444-8. Epub 2017 Jun 28. Lancet Oncol. 2017. PMID: 28668386 Clinical Trial.
Dose-dense and high-dose chemotherapy plus rituximab with autologous stem cell transplantation for primary treatment of diffuse large B-cell lymphoma with a poor prognosis: a phase II multicenter study.
Vitolo U, Chiappella A, Angelucci E, Rossi G, Liberati AM, Cabras MG, Botto B, Ciccone G, Gaidano G, Falchi L, Freilone R, Novero D, Orsucci L, Pavone V, Pogliani E, Rota-Scalabrini D, Salvi F, Tonso A, Tucci A, Levis A; Gruppo Italiano Multiregionale Linfomi e Leucemie (GIMURELL). Vitolo U, et al. Among authors: pavone v. Haematologica. 2009 Sep;94(9):1250-8. doi: 10.3324/haematol.2009.007005. Epub 2009 Jul 7. Haematologica. 2009. PMID: 19586937 Free PMC article. Clinical Trial.
First-line treatment for primary testicular diffuse large B-cell lymphoma with rituximab-CHOP, CNS prophylaxis, and contralateral testis irradiation: final results of an international phase II trial.
Vitolo U, Chiappella A, Ferreri AJ, Martelli M, Baldi I, Balzarotti M, Bottelli C, Conconi A, Gomez H, Lopez-Guillermo A, Martinelli G, Merli F, Novero D, Orsucci L, Pavone V, Ricardi U, Storti S, Gospodarowicz MK, Cavalli F, Sarris AH, Zucca E. Vitolo U, et al. Among authors: pavone v. J Clin Oncol. 2011 Jul 10;29(20):2766-72. doi: 10.1200/JCO.2010.31.4187. Epub 2011 Jun 6. J Clin Oncol. 2011. PMID: 21646602 Free article. Clinical Trial.
Lenalidomide plus cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab is safe and effective in untreated, elderly patients with diffuse large B-cell lymphoma: a phase I study by the Fondazione Italiana Linfomi.
Chiappella A, Tucci A, Castellino A, Pavone V, Baldi I, Carella AM, Orsucci L, Zanni M, Salvi F, Liberati AM, Gaidano G, Bottelli C, Rossini B, Perticone S, De Masi P, Ladetto M, Ciccone G, Palumbo A, Rossi G, Vitolo U; Fondazione Italiana Linfomi. Chiappella A, et al. Among authors: pavone v. Haematologica. 2013 Nov;98(11):1732-8. doi: 10.3324/haematol.2013.085134. Epub 2013 Jun 28. Haematologica. 2013. PMID: 23812930 Free PMC article. Clinical Trial.
Lenalidomide plus R-CHOP21 in elderly patients with untreated diffuse large B-cell lymphoma: results of the REAL07 open-label, multicentre, phase 2 trial.
Vitolo U, Chiappella A, Franceschetti S, Carella AM, Baldi I, Inghirami G, Spina M, Pavone V, Ladetto M, Liberati AM, Molinari AL, Zinzani P, Salvi F, Fattori PP, Zaccaria A, Dreyling M, Botto B, Castellino A, Congiu A, Gaudiano M, Zanni M, Ciccone G, Gaidano G, Rossi G; Fondazione Italiana Linfomi. Vitolo U, et al. Among authors: pavone v. Lancet Oncol. 2014 Jun;15(7):730-7. doi: 10.1016/S1470-2045(14)70191-3. Epub 2014 May 13. Lancet Oncol. 2014. PMID: 24831981 Clinical Trial.
Interim Positron Emission Tomography Response-Adapted Therapy in Advanced-Stage Hodgkin Lymphoma: Final Results of the Phase II Part of the HD0801 Study.
Zinzani PL, Broccoli A, Gioia DM, Castagnoli A, Ciccone G, Evangelista A, Santoro A, Ricardi U, Bonfichi M, Brusamolino E, Rossi G, Anastasia A, Zaja F, Vitolo U, Pavone V, Pulsoni A, Rigacci L, Gaidano G, Stelitano C, Salvi F, Rusconi C, Tani M, Freilone R, Pregno P, Borsatti E, Sacchetti GM, Argnani L, Levis A. Zinzani PL, et al. Among authors: pavone v. J Clin Oncol. 2016 Apr 20;34(12):1376-85. doi: 10.1200/JCO.2015.63.0699. Epub 2016 Feb 16. J Clin Oncol. 2016. PMID: 26884559 Free article. Clinical Trial.
Lenalidomide plus R-CHOP21 in newly diagnosed diffuse large B-cell lymphoma (DLBCL): long-term follow-up results from a combined analysis from two phase 2 trials.
Castellino A, Chiappella A, LaPlant BR, Pederson LD, Gaidano G, Macon WR, Inghirami G, Reeder CB, Tucci A, King RL, Congiu A, Foran JM, Pavone V, Rivera CE, Spina M, Ansell SM, Cavallo F, Molinari AL, Ciccone G, Habermann TM, Witzig TE, Vitolo U, Nowakowski GS. Castellino A, et al. Among authors: pavone v. Blood Cancer J. 2018 Nov 8;8(11):108. doi: 10.1038/s41408-018-0145-9. Blood Cancer J. 2018. PMID: 30410035 Free PMC article.
ABVD versus modified stanford V versus MOPPEBVCAD with optional and limited radiotherapy in intermediate- and advanced-stage Hodgkin's lymphoma: final results of a multicenter randomized trial by the Intergruppo Italiano Linfomi.
Gobbi PG, Levis A, Chisesi T, Broglia C, Vitolo U, Stelitano C, Pavone V, Cavanna L, Santini G, Merli F, Liberati M, Baldini L, Deliliers GL, Angelucci E, Bordonaro R, Federico M; Intergruppo Italiano Linfomi. Gobbi PG, et al. Among authors: pavone v. J Clin Oncol. 2005 Dec 20;23(36):9198-207. doi: 10.1200/JCO.2005.02.907. Epub 2005 Sep 19. J Clin Oncol. 2005. PMID: 16172458 Clinical Trial.
Improved outcome of patients with relapsed/refractory Hodgkin lymphoma with a new fotemustine-based high-dose chemotherapy regimen.
Musso M, Messina G, Di Renzo N, Di Carlo P, Vitolo U, Scalone R, Marcacci G, Scalzulli PR, Moscato T, Matera R, Crescimanno A, Santarone S, Orciuolo E, Merenda A, Pavone V, Pastore D, Donnarumma D, Carella AM, Ciochetto C, Cascavilla N, Mele A, Lanza F, Di Nicola M, Bonizzoni E, Pinto A. Musso M, et al. Among authors: pavone v. Br J Haematol. 2016 Jan;172(1):111-21. doi: 10.1111/bjh.13803. Epub 2015 Oct 12. Br J Haematol. 2016. PMID: 26458240 Free PMC article.
448 results